-
Jun 2008
Comparison of the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9: determination of inter system extrapolation factors
10th European ISSX Meeting.
May 18th–21st 2008, Vienna, Austria.
Download poster
-
Jun 2008
What is the level of expression of CYP2D6 in human liver? Influence of different calibration standards of the estimation of CYP2D6 abundance.
10th European ISSX Meeting.
May 18th–21st 2008, Vienna, Austria.
Download poster
-
May 2008
Prediction of the increased exposure to drugs in liver cirrhosis: a systems biology approach integrating prior information on disease with in vitro data on drug disposition.
10th European ISSX Meeting.
May 18th–21st 2008, Vienna, Austria.
Download poster
-
May 2008
Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp®V8).
10th European ISSX Meeting.
May 18th–21st 2008, Vienna, Austria.
Download poster
-
May 2008
Simulation of the effect of P-glycoprotein on drug absorption in the human gastrointestinal tract.
10th European ISSX Meeting.
May 18th -21st 2008, Vienna, Austria.
Download poster
-
May 2008
In vitro-in vivo extrapolation of the clearance of drugs by glucuronidation: Scaling factors for recombinant UGT1A1 data.
10th European ISSX Meeting.
May 18th -21st 2008, Vienna, Austria.
Download poster
-
May 2008
Cytochrome P450 turnover: methods for determining rates and implications for the prediction of drug interactions.
2nd Asian Pacific ISSX Meeting.
May 11th-13th 2008, Shanghai, China.
Download poster
-
Apr 2008
Mechanistic models of human pharmacokinetics to predict the effects of liver cirrhosis on the clearance of nine drugs.
American Conference on Pharmacometrics.
March 9th-12th 2008, Tucson, Arizona, USA.
Download poster
-
Oct 2007
Supersaturation properties of poorly soluble weak bases are key factors in determining oral drug absorption: a simulation study of nifedipine using the ADAM model (Simcyp v7.1).
EUFEPS & COST B25 Conference on Bioavailability and Bioequivalence:
Focus on Physiological Factors and Variability.
October 1st-2nd 2007, Athens, Greece.
Download poster
-
Oct 2007
Impact of variability in estimates of drug diffusion coefficient on the prediction of fraction absorbed from the gut (fa) using the ADAM model (Simcyp v7.1).
EUFEPS & COST B25 Conference on Bioavailability and Bioequivalence:
Focus on Physiological Factors and Variability.
October 1st-2nd 2007, Athens, Greece.
Download poster
-
Sep 2007
Experimental considerations in determining Inter System Extrapolation Factors required for prediction of human drug clearance from recombinantly expressed enzymes. DMDG Open Meeting, Cambridge, UK
Download poster
-
Jun 2007
A novel physiologically-based mechanistic model for predicting oral drug absorption: the advanced dissolution, absorption, and metabolism (ADAM) model.
4th World Conference on Drug Absorption, Transport and Delivery
(4th WCDATD)
June 20th-22nd 2007, Kanazawa, Japan.
Download poster
-
Jun 2007
Comparison of the “well-stirred” gut and the “QGut” models for predicting intestinal first-pass metabolism.
4th World Conference on Drug Absorption, Transport and Delivery
(4th WCDATD)
June 20th-22nd 2007, Kanazawa, Japan.
Download poster
-
Jun 2007
The impact of genetic polymorphism in CYP3A5 on the pharmacokinetics of the mixed CYP3A4/5 substrates midazolam and tacrolimus assessed by clinical trial simulation (CTS).
Download poster
-
Jun 2007
Assessing the relevance of genetic polymorphism in CYP3A5 in the kinetics of midazolam and tacrolimus: The importance of adequate study size.
Download poster
-
May 2007
Prediction of in vivo drug interactions from in vitro enzyme kinetic data: time-based versus steady state simulations.
Pharmaceutical Sciences World Congress (PSWC 2007)
Optimising Drug Therapy: An Imperative for World Health
22nd-25th April 2007, Amsterdam, Netherlands.
Download poster
-
May 2007
Bias in estimates of metabolic constants when applying the Michaelis-Menten equation to drugs exhibiting atypical enzyme kinetics.
Pharmaceutical Sciences World Congress (PSWC 2007)
Optimising Drug Therapy: An Imperative for World Health
22nd-25th April 2007, Amsterdam, Netherlands.
Download poster
-
May 2007
Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time) -based enzyme inhibition.
Pharmaceutical Sciences World Congress (PSWC 2007)
Optimising Drug Therapy: An Imperative for World Health
22nd-25th April 2007, Amsterdam, Netherlands.
Download poster
-
May 2007
Mechanistic Prediction of HIV Drug-Drug Interactions in Virtual Populations from in vitro Enzyme Kinetic Data: Ritonavir and Saquinavir.
Download poster
-
Oct 2006
Prediction of the oral clearance of midazolam using in vitro data from recombinantly expressed enzymes and inter system extrapolation factors.
Abstract published in:
Drug Metabolism Reviews A71, 38(S2), 41, 2006.
Download poster
-
Oct 2006
Prediction of the oral clearance of tolbutamimde in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data.
14th North American ISSX Meeting
October 22nd-26th 2006, Rio Grande, Puerto Rico.
Download poster
-
Sep 2006
Utility of data from recombinant expressed genetic variants of CYPs in predicting the influence of genotype on in vivo drug kinetics - the case for S-Warfarin.
35th Annual Meeting of American College of Clinical Pharmacology
September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in:
Journal of Clinical Pharmacology A27, 46(9), 1067, 2006.
Download poster
-
Sep 2006
Assessing the propagation of CYP2C9 polymorphism into the PK/PD of warfarin using clinical trial simulations (CTS).
35th Annual Meeting of American College of Clinical Pharmacology
September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in:
Journal of Clinical Pharmacology A28, 46(9), 1067, 2006.
Download poster
-
Sep 2006
Prediction of metabolic drug clearance in pediatric subjects and its sensitivity to different models for the development of CYP enzymes.
35th Annual Meeting of American College of Clinical Pharmacology
September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in:
Journal of Clinical Pharmacology A40, 46(9), 1070, 2006.
Download poster
-
Sep 2006
A meta-analysis of CYP3A4 abundance in human liver: use of different standards contributes to apparent heterogeneity in reported values.
35th Annual Meeting of American College of Clinical Pharmacology
September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in:
Journal of Clinical Pharmacology A82, 46(9), 1080, 2006.
Download poster
-
Sep 2006
The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using PBPK modelling.
35th Annual Meeting of American College of Clinical Pharmacology
September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in:
Journal of Clinical Pharmacology A18, 46(9), 1065, 2006.
Download poster
-
Jun 2006
Prediction of the inhibitory effects of ketaconazole and fluconazole on midazolam and zolpidem clearance from in vitro data using physiologically-based pharmacokinetic modelling.
In Vitro Stability of Human Recombinant Cytochrome P450 Enzymes
9th International Conference on Drug-Drug Interactions
June 20th-21st 2006, Seattle, WA, USA.
Download poster
-
Jun 2006
In-vitro stability of human recombinant cytochrome P450 enzymes.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Estimation of the kinetic parameters of mechanism-based inhibition of CYP2D6 by methylenedioxymethamphetamine (MDMA) in cryopreserved human hepatocytes.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA): differences between expressed enzyme systems and human liver microsomes.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
The use of recombinantly expressed standards for immuno-quantification of hepatic CYP3A5 can result in an underprediction of CYP3A5 abundance.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Modelling of the age related changes of human CYP enzymes for predicting drug disposition in neonates, infants and children.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Co-operativity in the in vitro kinetics of cytochrome P450 (CYP) mediated drug metabolism will have minimal impact on in vivo metabolic clearance.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Predicting drug interactions with selective serotonin reuptake Inhibitors (SSRIs): impact of non-specific binding and active uptake.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
The propagation of genetic polymorphism in CYP2C9 into tolbutamide pharmacokinetics: assessment using an intergrated model.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using physiologically-based pharmacokinetic modelling.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Differences in cytochrome P450 (CYP3A4) expression alone do not explain inter-individual variability in CYP3A mediated hepatic testosterone 6ß hydroxylase (TST6ßOH) activity.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jun 2006
Prediction of the oral clearance of S-warfarin in CYP2C9 genotypes from in vitro enzyme kinetic data.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.
Download poster
-
Jan 2006
Values of human hepatocellularity per gram of liver and associated variability for use in the prediction of human in vitro metabolic clearance.
Hepatocyte User Group (HUG) Meeting
January 26th-27th 2006, Copenhagen, Denmark.
Download poster
-
Nov 2005
Simulations to assess the propagation of the impact of genetic polymorphism
in CYP enzymes into PK and PD outcomes: warfarin and dextromethorphan
as examples.
AAPS Annual Meeting & Exposition
November 6th-10th 2005, Nashville, Tennessee, USA.
Download poster
-
Jun 2005
Genetic algorithms and their applications in PK/PD data analysis. Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
Incorporation of inter-individual variability into the prediction of in vivo
drug clearance.
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
The propagation of genetic polymorphism in CYP2C9 into warfarin pharmacokinetics: an integrated model.
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
The impact of study design on the estimation of parameters describing mechanism-based enzyme inhibition.
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
Inter-individual variability in the catalytic activity of CYP3A4 per unit of
enzyme (kcat).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
Prediction of xenobiotic clearance in humans: in vitro - in vivo extrapolation (IVIVE) vs allometric scaling (AS).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
Implications of the disparity in relative holo:apo-protein contents of different standards used for immuno-quantification of hepatic P450 3A4 (CYP3A4).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Jun 2005
A critical evaluation of the experimental design in reports of mechanism based inhibition (MBI) studies and the assessment of their implication for in vitro - in vivo extrapolation (IVIVE).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.
Download poster
-
Apr 2005
Inter- and intra-individual variability in gastro-intestinal physiology has significant effects on the prediction of fraction of dose absorbed (fa).
3rd World Conference on Drug Absorption, Transport & Delivery April 18th-20th 2005, Barcelona, Spain.
Download poster
-
Nov 2004
Genetic algorithms and their applications in PK/PD data analysis.
Pharmacokinetics U.K. 2004
November 17th-18th 2004, Holiday Inn, Belfast, Northern Ireland.
-
Feb 2004
Inter and intra-individual variability in physiological parameters of gastro-intestinal tract has significant effects on the predicted fraction of dose absorbed.
LogP 2004: The 3rd Lipophilicity Symposium
February 29th-March 4th 2004, Zurich, Switzerland.
Download poster
-
Feb 2004
Accounting for first pass gut metabolism improves the relationship between lipophilicity and in vivo permeability.
LogP 2004: The 3rd Lipophilicity Symposium
February 29th-March 4th 2004, Zurich, Switzerland.
-
Dec 2003
Population clearance prediction of 13 drugs using SIMCYP™.
Pharmacologist
44 (Supplement 1), LB87, 2002.
-
Oct 2003
Predicting metabolic drug-drug interactions for oral drugs: the impact of high transient concentrations of inhibitor and substrate during absorption.
European Journal of Pharmaceutical Sciences
20, 223-232, 2003.
-
Jul 2003
Physiologically based modelling of inhibition of metabolism to assess the relative potency of drug and metabolite: dextromethorphan vs dextrorphan using quinidine Inhibition.
British Journal of Clinical Pharmacology
56, 57-67, 2003.
-
Jul 2003
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.
British Journal of Clinical Pharmacology
56, 433-440, 2003.
-
Jun 2003
Prediction drug clearance allowing for the influence of P-glycoprotein activity using SIMCYP™.
The Proceedings of the 6th Congress of European Association for Clinial Pharmacology and Therapeutics.
152, 24th-28th June 2003, Istanbul.
-
Jul 2001
Prediction of fluconazole interaction with midazolam and triazolam: Incorporating population variability.
Proceedings of the British Pharmacological Society
July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.
Abstract published in:
British Journal of Clinical Pharmacology A26, 52(4), 484, 2001.
View abstract and full text options
-
Jul 2001
Reference values for human microsomal protein per gram of liver.
Proceedings of the British Pharmacological Society
July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.
Abstract published in:
British Journal of Clinical Pharmacology A10, 52(4), 471, 2001.
View abstract and full text options
-
Nov 2000
Incorporating interindividual variability into in vitro – in vivo extrapolation.
7th EUFEPS Conference
Optimising Drug Development: Strategies to Assess Drug Metabolism/Transport Interaction Potential – Towards a Consensus
November 13th-15th 2000, Basel, Switzerland.
-
Jul 1999
Incorporating variability into prediction of drug-drug interactions: moving from deterministic to a stochastic approach.
Mathematics in Medicine Initiative (MiMI), Compartmental Modelling and Pharmacokinetic Analysis
July 20th-22nd 1999, University of Warwick, United Kingdom.
-
Aug 1997
Metabolic variability in populations.
In: The Population Approach: measuring and managing variability in response, concentration and dose.
ECSC-EC-EAE 9-13, Brussels, Luxembourg, 1997.
-
Aug 1995
The determination of drug metabolising status in vivo: pharmacokinetic and statistical issues.
In: Advances in Drug Metabolism in Man.
(Eds. Pacifies GM & Fracchia GN)
ECSC-EC-EAE 37-55, Brussels, Luxembourg, 1995.
-
Aug 1995
Phenotyping populations: pharmacokinetic and statistical issues.
In: Variability and Specificity in Drug Metabolism.
(Eds. Alvan G, Balant LP, Bechtel PR et al.)
ECSC-EC-EAE 191-203, Brussels, Luxembourg, 1995.
-
Aug 1990
Pharmacokinetic-pharmacogenetic modeling – a basis for the display and detection of polymorphisms in drug metabolism.
In: Proceedings of European Consensus Conference on Pharmacogenetics.
(Eds. Alvan G et al.)
ECSC-EC-EAE 59-67 Brussels, Luxembourg, 1990.
-
Aug 1990
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism – statistical methods.
In: Proceedings of European Consensus Conference on Pharmacogenetics.
(Eds. Alvan G et al.)
ECSC-EC-EAE 43-52, Brussels, Luxembourg, 1990.